STOCKHOLM, Sweden, Aug. 11, 2005 (PRIMEZONE) -- Active Biotech:
-- All projects progressing in accordance with planned milestones -- Issue totaling approximately SEK 169 M completed -- oversubscribed by 43 percent -- Exercise of option to repurchase research facility in Lund -- Net sales: SEK 5.8 M (30.4) -- Operating loss: SEK 100.5 M (loss: 97.0) -- Loss after tax: SEK 110.3 M (loss: 76.6) -- Loss per share for the period: SEK 3.27 (loss: 2.27)